Pipeline
NeoImmuneTech, Inc. (NIT) is developing Hyleukin-7TM in collaboration with major cancer centers and universities in the US and South Korea, pursuing combination trials with leading immunotherapeutics such as immune checkpoint inhibitors, cancer vaccines and more. NIT pursues clinical development of key indication areas – cancer and lymphopenia,.
NIT is relentlessly conducting proof-of-concept animal studies in additional indications in order to strengthen our pipeline and broaden the proof of applicability of Hyleukin-7TM.
